Alnylam Pharmace. buy Shooter
Start price
06.02.23
/
50%
€214.05
Target price
06.02.24
-
Performance (%)
-24.78%
End price
07.02.24
€161.00
Summary
This prediction ended on 07.02.24 with a price of €161.00. The prediction for Alnylam Pharmace. disappointed with a performance of -24.78%. Shooter has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | -5.845% | -5.845% | 7.020% |
| iShares Core DAX® | -1.432% | 0.000% | 12.331% |
| iShares Nasdaq 100 | -0.386% | -0.595% | 4.688% |
| iShares Nikkei 225® | 1.448% | 5.269% | 18.051% |
| iShares S&P 500 | 0.114% | -0.217% | 1.388% |
Comments by Shooter for this prediction
In the thread Trading Alnylam Pharmace.
Die von Shooter gewählte maximale Laufzeit wurde überschritten